Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen.
Adult mice were injected subcutaneously with cells from a syngeneic metastasizing mammary cancer. Daily treatment with flurbiprofen starting before injection of the cancer cells reduced tumour growth and lengthened the survival of mice whose tumours were excised at 3 weeks. When low doses of radiotherapy and chemotherapy were given, additional treatment with flurbiprofen starting 25 days after injecting the cancer cells substantially inhibited tumour growth.
D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D051379:Mice; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009368:Neoplasm Transplantation; D011422:Propionates / Q000627:therapeutic use*; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000096:biosynthesis
D011422:Propionates; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D005480:Flurbiprofen